文献速递心力衰竭与心肌病

1988至2023年美国心力衰竭患病率、相关危险因素与健康负担趋势

Trends in the Prevalence, Associated Risk Factors, and Health Burden of Heart Failure in the United States, 1988 to 2023.
PubMed 文献 · J Am Coll Cardiol · 2025-11-26

该研究基于83,552名≥20岁门诊参与者(其中心衰3,078例)分析1988至2023年美国心衰患病率、危险因素及健康结局变化。心衰粗患病率从2.1%升至3.0%(增幅43%,95%CI 8%-91%),年龄标化患病率无变化;心衰患者中肥胖、糖尿病和慢性肾脏病患病率上升,而高血压、高胆固醇和心肌梗死病史下降,心血管和全因死亡率降低但非心血管死亡增加。

要点

  • 心衰患者中肥胖、糖尿病和慢性肾脏病患病率显著上升。
  • 心衰患者中心血管和全因死亡率下降,但非心血管死亡增加。

核心结论

  • 心衰危险因素谱发生重大转变:肥胖、糖尿病和慢性肾脏病患病率上升,而高血压、高胆固醇和既往心肌梗死下降。
  • 全因和心血管死亡率降低,但非心血管死亡增加部分抵消了全因死亡改善。

研究设计与样本

  • 研究使用具有全国代表性的83,552名≥20岁门诊参与者样本,其中心衰患者3,078例。
  • 评估自报心衰及主要危险因素的患病率,并报告2023年与1988年比较的患病率比(PR)。
  • 分析死因别死亡率趋势以及自报健康、身体功能和工作相关损害的趋势。

主要发现

  • 心衰患者中肥胖患病率从32.5%升至60.4%(PR 1.86,95%CI 1.36-2.55),糖代谢异常从48.6%升至69.2%(PR 1.42,95%CI 1.14-1.77),糖尿病从21.2%升至36.2%(PR 1.71,95%CI 1.28-2.29),慢性肾脏病从38.6%升至52.3%(PR 1.35,95%CI 1.08-1.70)。
  • 心衰患者中血压升高从80.7%降至49.1%(PR 0.61,95%CI 0.51-0.73),高胆固醇血症从71.5%降至22.6%(PR 0.32,95%CI 0.21-0.47),心肌梗死病史从59.3%降至42.1%(PR 0.71,95%CI 0.57-0.88)。
  • 观察到心血管和全因死亡率显著降低,但全因死亡改善部分被非心血管死亡增加所抵消。
  • 自报健康和身体功能随时间改善,但工作相关损害持续存在。

关键数值与推荐

  • 肥胖定义为体重指数≥30 kg/m2。
  • 血压升高定义为收缩压≥130 mm Hg和/或舒张压≥80 mm Hg。
  • 糖代谢异常定义为HbA1c≥5.7%。
  • 高胆固醇血症定义为总胆固醇≥200 mg/dL。
  • 慢性肾脏病定义为估算肾小球滤过率<60 mL/min/1.73 m2或白蛋白/肌酐比值≥30 mg/g。

临床怎么用

  • 心衰管理中应加强肥胖、糖尿病和慢性肾脏病的筛查与综合干预。
  • 尽管血压、血脂和心肌梗死病史患病率下降,仍需持续关注这些危险因素的防控。
  • 关注心衰患者非心血管死亡增加的趋势,完善全程健康管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The management heart failure (HF) and its risk factors has changed substantially in recent decades. OBJECTIVES: The authors sought to determine changes in the prevalence of HF, its underlying risk factors, and associated health outcomes from 1988 to 2023. METHODS: Using a nationally representative sample of 83,552 ambulatory participants (3,078 with HF) aged ≥20 years, we assessed the prevalence of self-reported HF and associated major risk factors, including obesity (body mass index [BMI] of 30 kg/m2 or higher), elevated blood pressure (systolic blood pressure of 130 mm Hg or higher and/or diastolic blood pressure of 80 mm Hg or higher), impaired glucose homeostasis (HbA1c of 5.7% or higher), hypercholesterolemia (total cholesterol of 200 mg/dL or higher), history of myocardial infarction (MI), and chronic kidney disease (estimated glomerular filtration rate <60 mL/min/1.73 m2 or albumin/creatinine ratio of 30 mg/g or higher). Prevalence ratios (PRs) comparing disease prevalence in 2023 to 1988 were reported. Cause-specific trends in mortality rates were also analyzed, as were trends in self-reported health, physical function, and work-related impairments. RESULTS: The crude prevalence of HF increased from 2.1% in 1988 (3.3 million adults) to 3.0% in 2023 (7.4 million adults); a 43% increase (95% CI: 8%-91%). There was no change in age-standardized prevalence (2.9% to 3.0%). Among respondents with HF, prevalence of obesity increased from 32.5% in 1988 to 60.4% in 2023 (PR: 1.86; 95% CI: 1.36-2.55), impaired glucose homeostasis from 48.6% to 69.2% (PR: 1.42 [95% CI: 1.14-1.77), diabetes from 21.2% to 36.2% (PR: 1.71 [95% CI: 1.28-2.29]), and chronic kidney disease from 38.6% to 52.3% (PR: 1.35 [95% CI: 1.08-1.70]). Elevated blood pressure decreased from 80.7% to 49.1% (PR: 0.61 [95% CI: 0.51-0.73]), hypercholesterolemia from 71.5% to 22.6% (PR: 0.32 [95% CI: 0.21-0.47]), and MI history from 59.3% to 42.1% (PR: 0.71 [95% CI: 0.57-0.88]). Trends that were more pronounced in respondents with HF compared with respondents without HF included reductions in elevated blood pressure, hypercholesterolemia, MI, and increases in the prevalence of obesity. Significant reductions in cardiovascular and all-cause mortality were observed, albeit the latter was partially offset by increases in noncardiovascular mortality. Self-reported health and physical function also improved over time, though work-related impairments persisted. CONCLUSIONS: From 1988 to 2023, the number of U.S. adults with HF increased from 3.3 to 7.4 million. Age-standardized prevalence was constant. This was accompanied by a major shift in underlying risk factor profiles, with a rising prevalence of obesity, diabetes. and chronic kidney disease paralleled by a decline in elevated blood pressure, elevated cholesterol, and previous MIs. Accompanying this has been a reduction in all-cause and cardiovascular deaths paralleled by an increase in noncardiovascular deaths. Finally, impairments in self-reported health and physical functioning among patients with HF have significantly decreased over time.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Sayed, Vasan, Harrell, et al. Trends in the Prevalence, Associated Risk Factors, and Health Burden of Heart Failure in the United States, 1988 to 2023. J Am Coll Cardiol. 2025. PMID: 41295936. doi:10.1016/j.jacc.2025.09.1503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。